Convalescent Plasma Falls Flat in New Study
Important finding shows convalescent plasma provides no significant benefit in severe COVID-19 cases.
Related Articles
PEN-FAST Forward: Accelerating Penicillin Allergy De-Labeling
PEN-FAST is a validated risk stratification tool that promotes efficient, safe, and effective de-labeling of penicillin allergies.
FDA Approves Antibiotic for Uncomplicated UTIs
Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible…
World Malaria Day: Addressing Challenges and Advances in Malaria Research
Photini Sinnis MD, professor at the Johns Hopkins School of Public Health and Deputy Director of the Johns Hopkins Malaria Research Institute, offers her insights…
Role of Memory B Cells in Protection Against Hepatitis C Reinfections
Study from the Journal of Hepatology aims to characterize immune responses associated with rapid natural clearance of HCV reinfection.
FDA Approves Antibiotic for Uncomplicated UTIs
Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible…
Foodborne Disease Outbreaks: 2024 Year-to-Date Insights
FDA recalls, allergy alerts, e coli & salmonella outbreaks, and more.
European Commission Approves Pfizer’s Antibiotic Combination for Multidrug Infections
With this approval, aztreonam-avibactam becomes the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating multidrug-resistant infections, including metallo-β-lactamase-producing bacteria.
TaiGen Completes Phase III Trials of TG-1000, Targets Influenza with Novel Antiviral Mechanism
Contagion® is a fully integrated news resource for practitioners and specialists to assist with the identification, diagnosis, treatment, and prevention of infectious diseases.
European Commission Approves Pfizer’s Antibiotic Combination for Multidrug Infections
With this approval, aztreonam-avibactam becomes the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating multidrug-resistant infections, including metallo-β-lactamase-producing bacteria.
Comparative Effectiveness of Remdesivir in Early COVID-19 Treatment
Evaluating inpatient mortality for patients without supplemental oxygen at admission across different variants of concern periods with insights from Dr. Andre Kalil.